250 related articles for article (PubMed ID: 37175923)
1. Novel Knowledge about Molecular Mechanisms of Heparin-Induced Thrombocytopenia Type II and Treatment Targets.
Mongirdienė A; Liuizė A; Kašauskas A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175923
[TBL] [Abstract][Full Text] [Related]
2. Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond.
Greinacher A; Warkentin TE
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):1-10. PubMed ID: 38066843
[TBL] [Abstract][Full Text] [Related]
3. Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes.
Krauel K; Fürll B; Warkentin TE; Weitschies W; Kohlmann T; Sheppard JI; Greinacher A
J Thromb Haemost; 2008 Dec; 6(12):2160-7. PubMed ID: 18983520
[TBL] [Abstract][Full Text] [Related]
4. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI.
Kasthuri RS; Glover SL; Jonas W; McEachron T; Pawlinski R; Arepally GM; Key NS; Mackman N
Blood; 2012 May; 119(22):5285-93. PubMed ID: 22394597
[TBL] [Abstract][Full Text] [Related]
5. Activated Platelet-Derived and Leukocyte-Derived Circulating Microparticles and the Risk of Thrombosis in Heparin-Induced Thrombocytopenia: A Role for PF4-Bearing Microparticles?
Campello E; Radu CM; Duner E; Lombardi AM; Spiezia L; Bendo R; Ferrari S; Simioni P; Fabris F
Cytometry B Clin Cytom; 2018 Mar; 94(2):334-341. PubMed ID: 28052584
[TBL] [Abstract][Full Text] [Related]
6. Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia.
Tutwiler V; Madeeva D; Ahn HS; Andrianova I; Hayes V; Zheng XL; Cines DB; McKenzie SE; Poncz M; Rauova L
Blood; 2016 Jan; 127(4):464-72. PubMed ID: 26518435
[TBL] [Abstract][Full Text] [Related]
7. Management of heparin-induced thrombocytopenia.
Warkentin TE; Greinacher A
Curr Opin Hematol; 2016 Sep; 23(5):462-70. PubMed ID: 27380556
[TBL] [Abstract][Full Text] [Related]
8. Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia.
McKenzie SE; Sachais BS
Curr Opin Hematol; 2014 Sep; 21(5):380-7. PubMed ID: 24992313
[TBL] [Abstract][Full Text] [Related]
9. Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia.
Kizlik-Masson C; Deveuve Q; Zhou Y; Vayne C; Thibault G; McKenzie SE; Pouplard C; Loyau S; Gruel Y; Rollin J
Blood; 2019 May; 133(22):2427-2435. PubMed ID: 30917957
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia.
Perdomo J; Leung HHL; Ahmadi Z; Yan F; Chong JJH; Passam FH; Chong BH
Nat Commun; 2019 Mar; 10(1):1322. PubMed ID: 30899022
[TBL] [Abstract][Full Text] [Related]
11. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban.
Warkentin TE
Thromb Res; 2003 May; 110(2-3):73-82. PubMed ID: 12893020
[TBL] [Abstract][Full Text] [Related]
12. The management of heparin-induced thrombocytopenia.
Keeling D; Davidson S; Watson H;
Br J Haematol; 2006 May; 133(3):259-69. PubMed ID: 16643427
[TBL] [Abstract][Full Text] [Related]
13. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies.
Krauel K; Hackbarth C; Fürll B; Greinacher A
Blood; 2012 Feb; 119(5):1248-55. PubMed ID: 22049520
[TBL] [Abstract][Full Text] [Related]
14. An overview of the heparin-induced thrombocytopenia syndrome.
Warkentin TE
Semin Thromb Hemost; 2004 Jun; 30(3):273-83. PubMed ID: 15282649
[TBL] [Abstract][Full Text] [Related]
15. Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin-induced thrombocytopenia.
Lee CSM; Selvadurai MV; Pasalic L; Yeung J; Konda M; Kershaw GW; Favaloro EJ; Chen VM
J Thromb Haemost; 2022 Apr; 20(4):975-988. PubMed ID: 35038779
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of heparin-induced thrombocytopenia and thrombosis.
Arepally G; Cines DB
Autoimmun Rev; 2002 May; 1(3):125-32. PubMed ID: 12849005
[TBL] [Abstract][Full Text] [Related]
17. Role of monocytes and endothelial cells in heparin-induced thrombocytopenia.
Madeeva D; Cines DB; Poncz M; Rauova L
Thromb Haemost; 2016 Oct; 116(5):806-812. PubMed ID: 27487857
[TBL] [Abstract][Full Text] [Related]
18. Heparin induced thrombocytopenia: pathogenetic, clinical, diagnostic and therapeutic aspects.
Castelli R; Cassinerio E; Cappellini MD; Porro F; Graziadei G; Fabris F
Cardiovasc Hematol Disord Drug Targets; 2007 Sep; 7(3):153-62. PubMed ID: 17896955
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for heparin-induced thrombocytopenia: Focus on Fcγ receptors.
Rollin J; Pouplard C; Gruel Y
Thromb Haemost; 2016 Oct; 116(5):799-805. PubMed ID: 27358188
[TBL] [Abstract][Full Text] [Related]
20. Heparin-induced thrombocytopenia: a ten-year retrospective.
Warkentin TE
Annu Rev Med; 1999; 50():129-47. PubMed ID: 10073268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
